lumacaftor · Orkambi

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Cystic Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
CA
  • ORKAMBI (lumacaftor/ivacaftor) is indicated for the treatment of cystic fibrosis (CF) in patients 1 year of age and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.
Product first approved 2016Health Canada
EU
  • Cystic fibrosis in patients homozygous for the F508del mutation in the CFTR gene (Orkambi, lumacaftor/ivacaftor; MAH Vertex Pharmaceuticals (Ireland) Limited)
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Cystic Fibrosis
NCT04235140 · Vertex Pharmaceuticals Incorporated
2020-02-24 – 2023-08-22 · Cystic Fibrosis
What this study did
NCT03601637 · Vertex Pharmaceuticals Incorporated
2018-09-07 – 2021-10-29 · Cystic Fibrosis
What this study did
NCT02544451 · Vertex Pharmaceuticals Incorporated
2015-08 – 2020-04 · Cystic Fibrosis
What this study did
NCT03125395 · Vertex Pharmaceuticals Incorporated
2017-05-12 – 2019-07-17 · Cystic Fibrosis
What this study did
NCT02797132 · Vertex Pharmaceuticals Incorporated
2016-05 – 2017-09 · Cystic Fibrosis
What this study did
NCT02390219 · Vertex Pharmaceuticals Incorporated
2015-03 – 2016-10 · Cystic Fibrosis, Advanced Lung Disease
What this study did
NCT02514473 · Vertex Pharmaceuticals Incorporated
2015-07 – 2016-09 · Cystic Fibrosis
What this study did
NCT01931839 · Vertex Pharmaceuticals Incorporated
2013-10 – 2016-04 · Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
What this study did
NCT01897233 · Vertex Pharmaceuticals Incorporated
2013-07 – 2015-10 · Cystic Fibrosis
What this study did
Phase 2 (6)
Cystic Fibrosis
NCT03625466 · Vertex Pharmaceuticals Incorporated
2018-08-10 – 2021-10-07 · Cystic Fibrosis
What this study did
NCT03061331 · Vertex Pharmaceuticals Incorporated
2017-01-31 – 2017-10-04 · Cystic Fibrosis
What this study did
NCT02709109 · Parion Sciences
2016-02 – 2017-09 · Cystic Fibrosis
What this study did
NCT01225211 · Vertex Pharmaceuticals Incorporated
2010-10 – 2014-04 · Cystic Fibrosis
What this study did
NCT00865904 · Vertex Pharmaceuticals Incorporated
2009-03 – 2009-12 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT04581408 · Istituto Auxologico Italiano
2021-06-15 – 2025-04-15 · Long QT Syndrome
What this study did
Phase 1 (6)
Cystic Fibrosis
NCT01910415 · Vertex Pharmaceuticals Incorporated
2013-06 – 2014-03 · Cystic Fibrosis
What this study did
NCT01768663 · Vertex Pharmaceuticals Incorporated
2013-01 – 2013-09 · Cystic Fibrosis
What this study did
NCT01899105 · Vertex Pharmaceuticals Incorporated
2013-07 – 2013-08 · Cystic Fibrosis
What this study did
NCT01216046 · Vertex Pharmaceuticals Incorporated
2010-10 – 2011-05 · Cystic Fibrosis
What this study did
NCT00966602 · Vertex Pharmaceuticals Incorporated
2009-09 – 2009-12 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT01888393 · Vertex Pharmaceuticals Incorporated
2013-06 – 2013-11 · Hepatic Impairment, Healthy
What this study did
Phase 4 (3)
Cystic Fibrosis
NCT03956589 · University Hospital, Antwerp
2018-10-01 – 2020-04-01 · Cystic Fibrosis
What this study did
NCT02875366 · Vertex Pharmaceuticals Incorporated
2016-09 – 2017-10 · Cystic Fibrosis
What this study did
NCT02823470 · Vertex Pharmaceuticals Incorporated
2016-06 – 2017-08 · Cystic Fibrosis
What this study did
Early phase / not applicable (3)
Cystic Fibrosis
NCT03894657 · Assistance Publique - Hôpitaux de Paris
2019-12-18 – 2022-05-12 · Cystic Fibrosis, Homozygous F508del Mutation
What this study did
NCT02858843 · Massachusetts General Hospital
2016-08-01 – 2018-05-01 · Cystic Fibrosis, Diabetes
What this study did
NCT02653027 · Massachusetts General Hospital
2018-01-01 – 2018-05-01 · Diabetes, Cystic Fibrosis
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lumacaftor (Orkambi): this drugApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta)ApprovedSmall moleculeCFTR, CFTRReliable signal
NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results).
NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results).
Ivacaftor (Kalydeco)ApprovedSmall moleculeCFTRPartial signal
NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1)
NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7)
Tezacaftor / Ivacaftor (Symdeko)ApprovedSmall moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek)ApprovedSmall moleculeCFTR, CFTRReliable signalNo reviewed efficacy summary in this indication
KB407Phase 1Gene therapy / editingCFTR (gene replacement)not yet gradedNo reviewed efficacy summary in this indication
VX-828Phase 1Small moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
LuvomeranDiscontinuedRNA / oligonucleotideCFTR (mRNA replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.